Aptevo Therapeutics Inc.
Close on Oct 19, 2026
- Market cap
- $1.91M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 14, 2026 | Before market open | – | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 13, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | After market close | – | $-2.23 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 11, 2025 | Before market open | – | $-8.40 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | After market close | – | $-4.39 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 14, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | – | $-0.48 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 5, 2024 | Before market open | – | – | – |
Press releases
Announcements Aptevo Therapeutics filed with the SEC
Aptevo to Showcase Multispecific Platform at SITC 2026 Annual Meeting
Other events · EX-99.1 to Form 8-K
Aptevo Advances Next-Generation Trispecific Candidate Toward Clinical Development
Other events · EX-99.1 to Form 8-K
Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML
Other events · EX-99.1 to Form 8-K
Aptevo Provides 2Q26 Business Update and Reports Second Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Aptevo Therapeutics Announces Exercise of Existing Warrants and PIPE for $4.5 Million Gross Proceeds
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Aptevo Therapeutics Announces Closing of Existing Warrants Exercise and PIPE for $4.5 Million Gross Proceeds
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone
Other events · EX-99.1 to Form 8-K
Aptevo Secures $1.5 Million Non-Dilutive Research Grant from the Andy Hill Care Fund to Advance APVO451, a Nectin-4-Targeted Trispecific Immunotherapy for Solid Tumors
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Aptevo and Niowave Launch Strategic Collaboration for Radiopharmaceutical Therapeutic Development, Includes Strategic Equity Investment by Niowave at Closing
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Aptevo Therapeutics Provides a 1Q26 Business Update; RAINIER on Track for 2026 Completion and Phase 2 Dose Selection
Results of operations · EX-99.1 to Form 8-K
Aptevo Provides State of the Business Report and 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Mipletamig Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
Other events · EX-99.1 to Form 8-K
Aptevo Therapeutics Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Aptevo Therapeutics Reports 3Q25 Financial Results And
Results of operations · EX-99.1 to Form 8-K
Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML
Other events · EX-99.1 to Form 8-K
Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules
Other events · EX-99.1 to Form 8-K
Aptevo Therapeutics Reports 2Q25 Financial Results And
Results of operations · EX-99.1 to Form 8-K
Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Other events · EX-99.1 to Form 8-K
Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Other events · EX-99.2 to Form 8-K
Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML
Material agreement · Other events · EX-99.3 to Form 8-K
Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan
Listing notice · Other events · EX-99.1 to Form 8-K
APTEVO THERAPEUTICS REPORTS 1Q25 FINANCIAL RESULTS AND
Results of operations · EX-99.1 to Form 8-K
Aptevo Therapeutics $2.0 Million Registered Direct Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Material agreement · Other events · EX-99.2 to Form 8-K
Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
Material agreement · Other events · EX-99.1 to Form 8-K
Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market
Material agreement · Other events · EX-99.2 to Form 8-K
20, March 2025 | Nasdaq: APVO
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
APTEVO THERAPEUTICS REPORTS 2024 FINANCIAL RESULTS AND
Results of operations · EX-99.1 to Form 8-K
CONFIDENTIAL 11, February 2025 | Nasdaq: APVO
Regulation FD disclosure · EX-99.1 to Form 8-K
100% of Patients Achieve Remission within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial
Other events · EX-99.1 to Form 8-K
Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects
Other events · EX-99.1 to Form 8-K
Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation
Other events · EX-99.1 to Form 8-K
APTEVO THERAPEUTICS REPORTS 3Q 2024 FINANCIAL RESULTS AND
Results of operations · EX-99.1 to Form 8-K
Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Other events · EX-99.1 to Form 8-K
Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules
Material agreement · Other events · EX-99.2 to Form 8-K